Hantz Financial Services Inc. Sells 8,261 Shares of Kenvue Inc. (NYSE:KVUE)

Hantz Financial Services Inc. decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 128,948 shares of the company’s stock after selling 8,261 shares during the period. Hantz Financial Services Inc.’s holdings in Kenvue were worth $2,983,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its stake in shares of Kenvue by 53.7% during the first quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock valued at $3,541,000 after buying an additional 57,679 shares during the last quarter. Atria Investments Inc lifted its stake in shares of Kenvue by 20.0% during the 1st quarter. Atria Investments Inc now owns 112,194 shares of the company’s stock worth $2,408,000 after acquiring an additional 18,663 shares during the last quarter. Cetera Investment Advisers boosted its holdings in Kenvue by 183.9% during the 1st quarter. Cetera Investment Advisers now owns 449,506 shares of the company’s stock valued at $9,646,000 after acquiring an additional 291,179 shares during the period. Cetera Advisors LLC grew its position in Kenvue by 202.0% in the 1st quarter. Cetera Advisors LLC now owns 212,097 shares of the company’s stock valued at $4,552,000 after acquiring an additional 141,858 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Kenvue by 78.6% in the first quarter. EverSource Wealth Advisors LLC now owns 4,155 shares of the company’s stock worth $89,000 after purchasing an additional 1,829 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.2 %

Shares of NYSE:KVUE opened at $24.08 on Friday. The company has a market capitalization of $46.17 billion, a PE ratio of 43.78, a P/E/G ratio of 2.19 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s fifty day simple moving average is $22.94 and its 200-day simple moving average is $20.99.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 earnings per share. As a group, equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.41%. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KVUE. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a report on Tuesday, September 24th. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Deutsche Bank Aktiengesellschaft boosted their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.